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Statement of translational relevance 
 
Oncolytic reovirus is a potentially attractive cancer therapeutic in view of its intrinsic 
targeting of cancer cells with dysregulated ras pathway signalling (and therefore relevance 
to a wide range of malignancies), lack of host toxicity and safety in phase I studies. The 
true potential of oncolytic viruses may only be realized in combination with other modalities 
such as chemotherapy, targeted therapy and radiotherapy. This study demonstrates 
synergistic cell kill in vitro and a survival benefit in vivo in malignant melanoma in murine 
models and human cell lines when reovirus was combined with a range of commonly 
available chemotherapeutics. The approach has direct relevance to the clinic and currently 
several phase I studies are evaluating reovirus/chemotherapy combinations. The finding 
that cisplatin almost negates the inflammatory response to reovirus may influence study 
design and ultimately allow an increase in the dose levels of reovirus without increasing 
systemic toxicity. 
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Abstract 
Purpose  
To test combination treatment schedules of reovirus and cisplatin chemotherapy in human 
and murine melanoma cell lines and murine models of melanoma. To investigate the 
possible mechanisms of synergistic antitumor effects. 
Experimental  design  
Effects of reovirus +/- chemotherapy on in vitro cytotoxicity and viral replication were 
assessed using MTS assay and plaque assay. Interactions between agents were 
assessed by combination index (CI) analysis. Mode of cell death was assessed by 
annexin/PI FACS based assays; gene expression profiling of single versus combination 
treatments were completed using the Agilent microarray system. Single agent and 
combination therapy effects were tested in vivo in two immune competent models of 
murine melanoma.  
Results 
Variable degrees of synergistic cytotoxicity between live reovirus and a number of 
chemotherapy agents were observed in B16.F10 mouse melanoma cells, most 
significantly with cisplatin (CI 0.42+/-0.03 ED50). Combination cisplatin and reovirus 
exposure led to increased late apoptotic/necrotic cell populations. Cisplatin almost 
completely abrogated the inflammatory cytokine gene upregulation induced by reovirus. 
Combination therapy led to significantly delayed tumour growth and improved survival in 
vivo (p<0.0001 and p=0.0003 respectively). Cisplatin had no effect on the humoral 
response to reovirus in mice. However, cisplatin treatment suppressed the cytokine and 
chemokine response to reovirus in vitro and in vivo.  
Conclusion 
The combination of reovirus and a number of chemotherapeutic agents synergistically 
enhanced cytotoxicity in human and murine melanoma cells lines in vitro, and murine 
tumours in vivo. The data supports the current reovirus/chemotherapy combination phase I 
clinical studies currently ongoing in the clinic. 
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Introduction 
 
There has been rapid pre-clinical and clinical development of viruses with oncolytic activity 
as anti-cancer therapeutics (1). As with other novel agents, the true potential of this 
approach to cancer treatment may only be realized in combination with other treatment 
modalities. Reoviruses (Respiratory Enteric Orphan Viruses) are ubiquitous, non-
pathogenic viruses that have been isolated from the human respiratory and 
gastrointestinal tract. They are non-enveloped icosahedral viruses with a segmented 
genome composed of double-stranded RNA. To date, reovirus infection in humans has not 
been associated with any known disease. Reovirus has innate oncolytic potential in an 
extensive range of murine and human tumor cells, and this is, at least in part, dependent 
on the transformed state of the cell (2,3). The precise mechanism of reoviral tropism and 
selective oncolysis in malignant cells is yet to be fully determined. In normal cells the 
presence of an intact double-stranded RNA-activated protein kinase system prevents the 
establishment of a productive infection. In malignant cells with activated Ras pathway (or 
upregulation of upstream or downstream components of the cell signaling pathway) 
through either Ras mutation or up-regulated epidermal growth factor receptor signaling (4, 
5, 6) this cellular antiviral response mechanism is perturbed, and viral replication and 
subsequent lysis of the host cell results. Reovirus has been shown to cause tumor 
regression after intralesional injections in immunodeficient mice and after systemic 
administration in immunocompetent mice (4, 7). In addition to the exploitation of oncogene 
signaling, reovirus activates the host immune response to potentially enhance antitumor 
responses through the efficient induction of type I interferons (8) and local inflammatory 
responses generated by reovirus-infected tumor cells causes bystander toxicity against 
reovirus-resistant tumor cells and activation of human myeloid dendritic cells (9). A number 
of phase I clinical studies of intratumoral or systemic reovirus as a single agent have been 
completed, with evidence of significant antitumor activity (10, 11) 
 
We have recently demonstrated synergistic in vitro antitumor activity when reovirus and 
radiotherapy were combined across a range of tumor cell lines. The combined effect was 
greatest in cell lines that were only moderately susceptible to reovirus alone. Interestingly, 
this effect did not depend on treatment sequence or schedule. Sensitisation was due to an 
increase in apoptosis in cells treated with combined therapy. Furthermore, in vivo studies 
using xenograft (HCT116, SW480) and syngeneic (B16.F10) tumors demonstrated 
enhanced activity of combined treatment relative to reovirus or radiation alone (12). To 
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date, oncolytic viruses have been safely combined with systemic chemotherapy in the 
clinic.  
In this study we have investigated the potential for increasing the antitumor effects of 
reovirus in murine and human melanoma cell lines in combination with chemotherapeutics 
and the possible mechanisms underlying these interactions. 
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Materials and methods 
 
Cell lines 
The mouse melanoma cell line B16.F10 was cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) at 37oC and 10% CO2.  K1735, another mouse melanoma, and L929, a 
murine fibroblast-like line, were cultured in DMEM at 37oC and 5% CO2.  The human 
melanoma cell line Mel 888 and two early passage melanoma lines SM and OM (passage 
22 and 24 respectively; both cell lines were derived from metastatic malignant melanoma 
deposits and were positive for S100 and HMB45 staining), were cultured in RPMI 1640 
Medium at 37oC and 5% CO2.  All media were supplemented with 2mM GlutaMAX-1 
supplement (Invitrogen), 100 units/ml penicillin, and 100 units/ml streptomycin (Sigma) and 
either 10% (v/v) fetal calf serum (FCS) for routine passage or 2% (v/v) FCS for 
experimental work. 
 
Reovirus stocks and chemotherapeutic agents 
Reovirus type 3 Dearing strain Reolysin® was obtained from Oncolytics Biotech. Inc. 
(Calgary, Canada). Virus stock titer and virus stability was measured by standard plaque 
assay of serially diluted samples on L929 cells. Six-well plates were seeded with 1 x 106 
L929 cells per well and infected with dilutions of viral stocks. After 3h incubation at 37oC, 
the virus solution was removed and the wells were overlaid with a 1:1 mixture of 2% 
SeaPlaque agarose (Cambrex Bio Science Rockland, Inc, ME) and 2 x MEM (Invitrogen) 
supplemented to a final concentration of 5% (v/v) FCS, 100 units/ml penicillin/streptomycin 
and 2mM GlutaMAX-1. Wells were stained with 500µL 0.03% neutral red (Sigma) in PBS 
72h post-infection and plaques were counted 3 to 4 h later. 
 
Cisplatin (cis diamminedichloroplatinum; Mayne Pharma Plc, UK), DTIC (dacarbazine; Ben 
Venue Laboratories, Inc, Bedford, OH), gemcitabine (Ely Lilly and Co., Indianapolis, IN), 
paclitaxel (Bristol-Myers Squibb Company, New York, N.Y.) and carboplatin (Bristol-Myers 
Squibb Company, New York, N.Y.) were all obtained from Royal Surrey County Hospital 
pharmacy. 
 
In vitro survival assay 
Cells were plated in 96-well plates at a density of 7.5 x 103 cells per well. After 24 hours, 
they were infected with known dilutions of reovirus and chemotherapeutic drug, either 
alone or in combination. After 48h incubation, cell viability was quantified using the 
 7
CellTiter 96 AQueous One Solution Cell Proliferation Assay reagent 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS; Promega) 
according to manufacturer’s instructions. Briefly, 20µL of MTS reagent was added to each 
well and following incubation at 37oC for 1-4 hours, absorbance was measured at 495nm. 
Survival was calculated as a percent compared to untreated cells. All experiments were 
repeated at least five times. 
 
In vitro synergy assay 
The effect of the combination of reovirus and chemotherapy on cell proliferation was 
assessed by calculating combination index (CI) values using CalcuSyn software (Biosoft, 
Ferguson, MO). Derived from the median-effect principle of Chou and Talalay (13), the CI 
provides a quantitative measure of the degree of interaction between two or more agents. 
A CI of 1 denotes an additive interaction, >1 antagonism and <1 synergy. Experiments 
were performed as described for the in vitro survival assay using 4, 2, 1, 0.5 and 0.25 
times the calculated median effective dose (ED50) of each agent in a constant ratio 
checkerboard design.  
 
Reovirus one-step growth curves 
Test cells were seeded overnight and then infected with reovirus MOI 10 in DMEM with 
2% FCS. At various times after infection, samples were transferred to -80oC. Following 
three freeze-thaw cycles between -80oC and room temperature, lysates were collected 
and virus titre determined by plaque assay as described above. 
 
Inactivation of reovirus by UV-irradiation and heat  
Reovirus was UV inactivated by exposing 50µL aliquots of viral stock at 1.2 x 1010 pfu/mL 
to 720 millijoules irradiation using a Stratalinker UV Crosslinker 2400 (Stratagene, LA Jolla, 
CA) to cross link viral RNA. Heat inactivation was performed by heating 200µL aliquots of 
viral stock at 1 x 109 pfu/mL for 20min at 60oC.  
 
FACS analysis of cell survival and apoptosis 
Following overnight seeding, B16.F10 cells were treated with 50µM cisplatin and/or 
reovirus MOI 1 for 48h. Adherent and non-adherent cells were collected, washed in cold 
PBS, re-suspended at 1 x 106 in 500µL PBS and then incubated for 15 min at room 
temperature in the dark in cold 1 x binding buffer containing Annexin V-FITC antibody, 
according to manufacturer’s instructions (Merck Biosciences Ltd). The cells were pelleted 
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and re-suspended in cold 1 x binding buffer. Cells were stained with 10µL propidium iodide 
(PI) at 30µg/mL and analyzed on a Coulter Epics XL flow cytometer (Beckman Coulter) 
using EXPO32 ADC software (Beckman Coulter). 
 
Caspase inhibition assay 
B16.F10 cells were seeded overnight and then treated for 45min with 50µM Z-VAD-FMK 
(R&D Systems) prior to exposure to 50µM cisplatin and/or reovirus MOI 1 in DMEM with 
2% FCS for 24, 48 or 72h. Cell viability was quantified at these time points as described 
above for the in vitro survival and synergy assays. 
 
Microarray analysis 
Total RNA was extracted from test cells using the Qiagen RNeasy mini kit (Qiagen Inc) 
according to the manufacturer’s recommendations. Fluorescent-labeled cRNA was 
produced using the One Color Low RNA Input Linear Amp Kit (Agilent Technologies UK 
Ltd) and purified using RNeasy Mini Kit (Qiagen). The labeled cRNA was fragmented and 
hybridized overnight to Whole Mouse Genome (4x44K) Oligo Microarray slides (Agilent) 
using the Agilent Gene expression Hybridization Kit (Agilent). The slides were washed and 
scanned using an Agilent DNA Microarray Scanner (Agilent). Data was extracted using the 
Agilent Feature Extraction software and was subsequently analysed using GeneSpring 
(Agilent), using the fold change of each gene based upon normalised data. Only changes 
calculated to be significant (p<0.05) are included in the results. 
 
In vivo studies 
All procedures were approved by United Kingdom Home Office and institutional boards. All 
animal experiments were repeated at least three times. Mice were purchased from B and 
K Universal Ltd. Subcutaneous tumours were established in the flank of each mouse by 
injecting 5 x 105 cells in a volume of 100µL Hanks Balanced Salt Solution (HBSS; Sigma). 
Animals were examined thrice weekly for tumour development. Three orthogonal tumour 
diameters (d1, d2, and d3) were measured using Vernier callipers and tumour volume was 
calculated from the formula V = π/6 d1·d2·d3. Animals were killed when tumour size 
exceeded 15mm in any one dimension.  
 
Reovirus (1 x 108 pfu in 100µL volume) was administered using a single cutaneous 
puncture site. Once in a s.c. location, the 25-gauge needle was redirected along multiple 
tracks within the tumour to achieve maximal dispersal of the reovirus. It was possible to 
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achieve direct intratumoral injection without backflow of the injectate. Cisplatin (2.5 mg/kg) 
was administered intraperitoneally in a total volume of 100µL. Control animals received an 
equivalent volume of HBSS alone. 
 
Virus titration from tumor and organs 
Tumor and organs (heart, lungs and liver) were weighed and homogenized in a 
TissueLyser (Qiagen) at 30Hz for 2 minutes. Following centrifugation to clarify the virus 
lysate, virus titer was determined by plaque assay on L929 cells as described above and 
expressed as plaque forming units (pfu)/g tissue. 
 
Serum analysis for presence of neutralizing anti-reoviral antibodies (NARA) 
The methodology used for analysis of NARA has been reported recently (14). Briefly, 
serum samples from individual mouse groups day 4 post treatment were batched and 
analyzed simultaneously. To determine a suitable virus dilution for subsequent assay, 
L929 cells were plated in 96-well plates at 2.5 x 104 cells/well and incubated overnight at 
37oC and 5% CO2. Reovirus stock (3.5 x 1010/ml) was added in two dilution series (2-fold 
and 10-fold) across the plate such that the final dilutions of the two series were 1:32,768 
and 1:1012. After 2 hours, the reovirus inoculum was removed and replaced with growth 
medium. After a further 48 hours, cell survival was measured by MTT assay. In order to 
establish a suitable dilution series for the estimation of neutralizing antibody levels in the 
serum, the above experiment was repeated with a constant titer of reovirus (known to 
cause 80% cell death) that was pre-incubated with a dilution series of goat polyclonal anti-
reoviral antibody and cell survival was measured at 48 hours by MTT assay.  
 
Cytokine analysis  
Culture supernatant was collected from B16.F10 cells treated with either reovirus (MOI 1) 
or cisplatin (50μM) either alone or in combination at 0, 6, 12, 24, 48 and 72h post 
treatment. Samples were stored at -80oC prior to analysis using a Mouse Bio-Plex 
Cytokine Assay (Bio-Rad) according to the manufacturer’s instructions. Levels of IL-1α, 6, 
12 (p70), 17, MIP-1α, and RANTES were measured in 50µL of cell supernatant, carried 
out in duplicate.  
 
Serum was collected on day 4 from C57BL/6 mice bearing B16.F10 tumors and treated 
with reovirus and cisplatin alone or in combination as described above on days 0 and 3. 
Serum samples were stored at -80oC prior to analysis for cytokines as described above. 
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Statistical analysis 
Comparisons between groups were done using the t test and 2-way ANOVA. Survival 
curves were estimated using the Kaplan-Meier method, and significance was assessed 
using the 2 and logrank test. Statistical analysis was performed using GraphPad Prism 4 
(GraphPad Software Inc.). 
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Results 
 
Reovirus cytotoxicity in NIH3T3, L929 and tumor cell lines 
The effect of reovirus infection over 48 hours was assessed in murine and human 
malignant melanoma cell lines, L929 cells and NIH3T3 fibroblasts. Cells were infected with 
reovirus at MOI from 0.001 to 100. Differential sensitivity to reovirus across the cell lines 
was observed. As expected, L929 cells were extremely sensitive to reoviral cytoxicity with 
less than 1% survival at MOI 0.01 at 48 hours. Figure 1a demonstrates the superiority of 
reovirus cytotoxity in B16.F10 lines compared to NIH3T3 cells where toxicity was only 
observed at high (≥10) MOI. Consistent with this observation was the ability of B16.F10 
cell to support viral replication to a higher degree than NIH3T3 cells, Fig 1b.  
 
Reovirus cytotoxicity is enhanced by combination with cisplatin 
B16.F10 cells were infected with reovirus at a range of MOIs from 0.01 to 1 at cell 
concentration of 7.5 x 103/well for 48 hours, either alone or with concomitant 10 or 100µM 
cisplatin (Fig 1c). An MTS survival assay was performed after 48 hours. The addition of 
cisplatin significantly enhanced tumor kill compared to reovirus alone across all MOIs in a 
cisplatin dose dependent manner (2-way ANOVA, p<0.0001).  
 
Synergistic interaction between reovirus and chemotherapeutic agents in malignant 
melanoma cell lines 
The effect of the combination of reovirus and chemotherapy on cell proliferation was 
assessed by isobologram analysis by calculating combination indices (CI). The CI provides 
a quantitative measure of the degree of interaction between two or more agents. A CI of 1 
denotes an additive interaction, >1 antagonism and <1 synergy. Experiments were 
performed using 4, 2, 1, 0.5 and 0.25 times the calculated median effective dose (ED50), 
of each agent in a constant ratio checkerboard design. Chemotherapy and reovirus were 
administered to cells concomitantly. 
 
The combination of reovirus and the chemotherapeutic agents cisplatin, dacarbazine, 
gemcitabine, paclitaxel and carboplatin on B16.F10 cells was assessed. We observed 
synergistic cell kill with all agents. This was more pronounced with cisplatin and paclitaxel 
with CI values at the ED50 of 0.42 ± 0.03 and 0.44 ± 0.09 respectively (Table 1a). We 
further evaluated the combination of cisplatin (as it was associated with the lowest CI) with 
another murine malignant melanoma cell line K1735, and human malignant melanoma 
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lines Mel 888, SM and OM (early passage lines, described in the materials section). 
Synergistic effects of combined agents were observed with the early passage lines, but 
with higher CI values at ED50. However, the combination was antagonistic in the Mel 888 
cell line with a CI of 1.37 ± 0.02 at ED50 (Table 1b). 
 
Live virus is required for efficient cell killing 
We established that only live, and not inactivated, virus is capable of cytotoxicity, either 
alone or in combination with cisplatin.  
 
B16.F10 cells were treated with live, heat inactivated or UV-inactivated virus for 48 hours 
at MOIs up to 100, and survival was assessed by MTS assay. Live virus resulted in the 
most efficient cell kill; this effect was markedly reduced at all but the highest MOI after UV-
inactivation, and almost completely negated by heat inactivated virus (Fig 1d).  
 
Live, heat inactivated and UV-inactivated reovirus was combined with cisplatin at a fixed 
ratio of cisplatin to reovirus (12µM cisplatin to MOI 1 reovirus) over five two-fold dilutions 
for 48 hours. The combination of live reovirus with cisplatin enhanced cell kill compared to 
cisplatin alone. This enhancement of cell kill was not apparent when heat inactivated or 
UV-inactivated reovirus was used (Fig 1e) 2-way ANOVA p<0.0001. 
 
Enhanced apoptotic cell death with cisplatin and reovirus combination  
The nature of the synergy of cell kill with reovirus and cisplatin treatment observed was 
further investigated. We assessed the mode of cell death of B16.F10 cells treated with 
reovirus MOI 1, cisplatin 50µM or both agents together, at 24 and 48 hours by annexin/PI 
staining (Fig 2a and b). At 24 hours, there was a small increase in late apoptotic/necrotic 
population (A+PI+) in all groups, but slightly more so in the combination. By 48 hours, this 
effect had increased considerably with the majority of cells in the combination group A+PI+ 
and concomitant reduction of intact cells (A-PI-). The effect of reovirus alone also caused a 
degree of apoptotic death in this cell line. 
 
Caspase inhibition assay 
B16.F10 cells were seeded overnight and then treated with the pan-caspase inhibitor Z-
VAD-FMK prior to exposure to 50µM cisplatin and/or reovirus MOI 1 (Fig 2c-e).  The 
viability of cells treated with reovirus alone was reduced to 25% at 72 hours; addition of Z-
VAD-FMK to reovirus infected cells significantly reversed the reovirus induced cytotoxicity 
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suggesting reovirus cytotoxicity was through a caspase mediated apoptotic pathway. No 
similar reversal was seen with cisplatin alone, but in combination with reovirus some 
reversal was observed. 
 
Gene expression profile of B16.F10 treated with cisplatin, reovirus or combination 
We investigated the effect of individual agents and their combination on global gene 
expression. Total RNA was extracted from B16.F10 cells after exposure to cisplatin 
(100µM), reovirus (MOI 25) or both at two time points. Significant changes in gene 
expression were observed only after 24 hours (12 hour data not shown). The effects of 
reovirus alone included the upregulation of proinflammatory cytokines, apoptosis genes, 
MHC class I, oncogenes such as Rous sarcoma, and interestingly epidermal growth factor 
receptor 1 (EGFR1). A five-fold increase in expression of EGFR1 was confirmed by 
quantitative PCR (data not shown). Cisplatin alone was associated with increases in 
apoptosis genes such as Fos. The expression profile with combined cisplatin and reovirus 
was almost identical to that of cisplatin alone with almost complete abrogation of 
inflammatory cytokine expression. Only sonic hedgehog (Shh) expression appeared to be 
uniquely upregulated as a result of the combined treatments (Figure 3). 
 
Combined reovirus and cisplatin treatment enhances tumor growth delay in two 
immune competent murine models of malignant melanoma 
The in vivo effects of combined reovirus and cisplatin were evaluated in two models in 
view of the observed in vitro synergy: B16.F10 cells in C57/BL6 mice and K1735 in C3H 
mice. For both models, 5 x 105 cells were implanted subcutaneously. Treatment was 
initiated when tumors reached an average diameter of 4.5-5.5mm at approximately 10-12 
days for B16.F10 and 8-10 days for K1735. Mice were treated with intratumoral reovirus, 
intraperitoneal cisplatin or both on day 0 and day 3. Control mice received the same tumor 
inoculum and were treated with an equivalent volume of saline i.t. and i.p. administered in 
an identical manner. There were no obvious toxic effects of single agent or combination 
treatments in all mice treated, and experiments were concluded as a result of tumor 
growth reaching 15mm in any one dimension. 
  
In the B16.F10 C57BL/6 model, the combination of cisplatin and reovirus resulted in the 
most effective response in terms of tumor growth retardation (2-way ANOVA p<0.0001), 
although both cisplatin and reovirus monotherapies resulted in delayed tumor growth (Fig 
4a). The median survival for the control, cisplatin, reovirus and combination groups were 6, 
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8, 12 and 17 days respectively (Fig 4b) logrank test p=0.0003. We found a similar 
advantage for combination therapy in K1735 tumor/ C3H mouse model (data not shown).  
 
Viral replication in tumors and organs of treated mice 
We evaluated viral replication in tumours and organs at day 4 post therapy. B16.F10 
tumours were seeded on the flanks of C57BL/6 mice. Mice were treated with reovirus i.t. 
either alone or in combination with i.p. cisplatin on days 0 and 3, and following sacrifice on 
day 4 viral titre in tumour, liver, lungs and heart was determined using plaque assay (Fig 
5a). The highest viral yield was in resected tumour as expected, with over three times 
more virus detected in mice receiving the combination treatment than those receiving 
reovirus alone. Of the organs tested, the liver supported most viral growth, but much less 
(more than 5 logs) than tumour. No difference in virus titre in the liver, lungs or heart was 
observed between treatment with reovirus alone or in combination with cisplatin.  
 
Applying the same approach, we evaluated viral yield from organs from similarly treated 
cohorts of mice at point of sacrifice when tumour had reached maximum allowed size 
(15mm in any dimension) and/or ulcerated. After treatment with reovirus alone (median 
10.5 days), virus grew from all tumors and occasionally in the heart and liver. However, in 
combination with cisplatin (median 10 days), virus was grown from 3/6 tumors and also 4/6 
livers (Table 1c).  
 
Cisplatin does not affect the humoral response to reovirus 
The antitumor effects of reovirus have been enhanced by the co-administration of agents 
which reduce the humoral response to reovirus (5). This response is vigorous and is 
generally initiated within 48 hours. Abrogation of the humoral response results in increased 
viral effects, both antitumor and organ toxicity (15). Using a recently reported assay (14), 
we assessed the neutralizing anti-reovirus antibody (NARA) response to reovirus and 
reovirus/cisplatin combination in C57BL/6 mice. We found equivalent endpoint titers in 
both groups indicating that cisplatin did not affect the NARA response to reovirus when 
administered concomitantly (Fig 5b). 
 
Cisplatin reduces inflammatory cytokine response to reovirus 
The microarray analysis of B16.F10 cells treated with reovirus and cisplatin in combination 
demonstrated marked reductions in the expression of a range of pro-inflammatory cytokine 
genes. Culture supernatant was collected from B16.F10 cells treated with either reovirus 
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(MOI 1) or cisplatin (50μM) alone or in combination at 0, 6, 12, 24, 48 and 72h post 
treatment. Samples were stored at -80oC prior to analysis using a Mouse Bio-Plex 
Cytokine Assay. At 48 hours, concomitant exposure of tumor cells to reovirus and cisplatin 
resulted in a marked reduction, and in some cases almost complete abrogation, in 
cytokine production in a range of Th1 and Th17 cytokines as well as MIP-1α and RANTES, 
(Fig 5c).  
 
This was further evaluated in the in vivo model. Blood was collected from B16.F10 tumor 
bearing mice on day 4 following treatment as described above and the serum was 
assessed for cytokines by cytometric bead array in the same way as the in vitro 
experiment. Once again the concomitant administration of cisplatin markedly reduced the 
production of the same cytokines (Fig 5d).  
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Discussion 
 
In this study, we have demonstrated evidence of synergistic anti-cancer activity of 
oncolytic wild type reovirus with chemotherapy in a range of murine and human melanoma 
cell lines in vitro plus two in vivo models of murine melanoma. Metastatic malignant 
melanoma is a particularly aggressive cancer which has a modest response to 
conventional chemotherapy and therefore justifiably a target for novel cancer therapies 
(16). Synergistic cell kill was observed across a number of chemotherapeutic agents with 
reovirus; cisplatin was selected for detailed evaluation following the demonstration of 
marked in vitro synergy, the documented clinical activity (albeit modest) of cisplatin in 
advanced melanoma (as both a single agent and in combination), and that for future 
human studies, a reovirus /cisplatin combination would be feasible as patients’ disease 
may have already progressed while on dacarbazine, the current chemotherapeutic 
standard of care. 
 
A number of chemotherapy/oncolytic virus combinations have been evaluated to date, and 
have been shown to result in marked antitumor effects without compromising safety. The 
adenovirus Onyx-015 enhanced clinical efficacy by combining intratumoral Onyx-015 with 
systemic cisplatin and 5-fluorouracil (5FU) when compared to chemotherapy alone (17). 
E1A-expressing adenoviral E3B mutants combined with cisplatin and paclitaxel (18) 
showed synergistic activity in vitro and in vivo. A combination of oncolytic herpesviruses 
such as G207, HSV-1716, or NV1066, with chemotherapeutic agents shown higher 
antitumor activity than treatment with the virus alone. G207 combined with cisplatin, and 
HSV-1716 with mitomycin C resulted in synergistic activity in vitro and in vivo (19, 20, 21, 
22). The mechanism underlying the observed synergy is incompletely understood in these 
examples. Cell kill has in some cases been due to enhancement of viral replication leading 
to increased cytolysis (23, 20, 24). However, no increase in viral replication was observed 
in other studies such as the NV1020 in combination with 5-FU, SN38 (irinotecan), or with 
oxaliplatin where viral replication was clearly reduced if chemotherapeutics were added 
before, simultaneously, or after virus treatment (25). Other similar combination studies 
have shown either no effect of chemotherapeutics on viral replication (26,27, 28), or 
actually reduced viral replication (29). Recently, synergistic cytotoxic effects of rat 
parvovirus H-1PV and gemcitabine in a pancreatic cancer model were observed in 
gemcitabine-resistant cells lines (30).  
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Recently completed phase I studies by our group and others using Reovirus type 3 
(Dearing) have confirmed its potential as an anticancer agent as well as its safety and 
tolerability in humans (10,11). It is most likely that reovirus may achieve its potential by a 
combination approach with other modalities. The aim of combination treatment is to exploit 
additive or synergistic effects between agents, allow reovirus to target drug resistant 
subpopulations of tumor cells, utilize chemotherapy to improve the biodistribution or 
penetrance of reovirus in the tumor, and also for the attenuation of local and systemic 
immune responses to reovirus allowing virus to persist in the tumor environment for longer.  
 
We recently reported that the combination of reovirus and radiotherapy synergistically 
enhances cytotoxicity in a range of tumor cells through the enhancement of apoptosis in 
vitro, with confirmation of synergy in vivo (12). Consistent with our findings in human 
melanoma lines (9), where reovirus induced cytotoxicity of human melanoma cell lines was 
reversed with the addition of a pan caspase inhibitor ZVAD; when B16.F10 cells were 
treated in combination with cisplatin, partial reversal was observed suggesting at least 
some of the treated cells were dying through reovirus-associated apoptotic death 
mechanisms as cisplatin induced apoptosis is not thought to be caspase dependent.  
Annexin/propidium iodide staining indicated significant proportions of late 
apoptotic/necrotic cells rather than purely apoptotic cell death which may explain the 
partial reversal of cytotoxicity with ZVAD inhibition. Analysis of reovirus distribution in 
organs 4 days post injection indicated increased intratumoral viral replication with 
combination therapy. This appears a little at odds with the observed in vitro synergy and 
increased apoptosis. Consistent with recent reports with an oncolytic herpes simplex virus, 
it may be that the apoptotic effects of cisplatin may have altered tumor architecture and 
interstitial pressure to facilitate increased viral uptake and diffusion, thereby allowing more 
viral replication (31). Furthermore, the observation of high levels of reovirus in tumour in 
the combination group, which then were reduced to lower levels than reovirus alone may 
be explained by the increased tumour destruction in the combination group, and thereby 
less tumour mass later to support viral replication. The persistence of reovirus in liver 10 
days post treatment may raise, theoretically, potential safety issues but to date the clinical 
studies of reoviral therapy as a single agent or in combination with chemotherapy have not 
identified significant hepatotoxicity.  
 
Gene expression profiling of reovirus treated tumor cells versus controls showed marked 
upregulation of proinflammatory cytokines and activation of pro-apoptosis genes such as 
 18
NF-κB.  Similar effects have been reported in previous microarray analyses of reovirus 
infected HEK293 cells and murine neural cells (32, 33). Notably, we found co-treatment 
with cisplatin in vitro and in vivo markedly reduced inflammatory cytokine response to 
reovirus. The clinical implications of this may be the possibility of escalating the reovirus 
dose delivered to enhance tumor kill. Reovirus treatment alone also increased the 
expression of EGFR1 in B16.F10 cells as well as other murine and human tumor cell lines 
(data not shown); although this too was prevented by co-treatment with cisplatin. EGFR 
has been shown to enhance reoviral infection efficiency by what would appear to be the 
opportunistic use of an already activated signal transduction pathway (34). The 
transfection of relatively resistant cell lines with the EGFR gene confers significantly higher 
susceptibility to reovirus infection (34) and so an increase in endogenous EGFR1 
expression could be expected to potentiate reovirus infection and enhance cell killing. 
 
Only one gene was found to be up-regulated uniquely by the combination of cisplatin and 
reovirus - the secreted signaling protein Shh, part of a key signaling pathway involved both 
in early development and cancer. In the latter, Shh secretion may modify the behavior of 
stromal cells to facilitate metastasis, although malignant cells that express high levels of 
Shh may also require Shh signaling to survive and are thus sensitive to Shh antagonists 
(35). Future work will determine whether cells treated with cisplatin and reovirus become 
more sensitive to Shh antagonism. 
 
The host immune response to oncolytic viruses may ultimately influence their success in 
the clinical arena, both in terms of humoral responses to neutralize virus and also the 
priming of antigen specific T cells from in situ tumor destruction after capture by local 
antigen presenting cells and migration to regional lymph nodes. Our recent clinical study 
showed the induction of a brisk NARA response to repeated systemic reovirus infusion 
(15). In this study, concomitant administration of cisplatin did not abrogate this response. 
However, in combination, cisplatin acted to drastically reduce the inflammatory cytokine 
response of B16.F10 cells to reovirus in vitro and in vivo. Cytokine and chemokine 
production by tumor cells has been extensively reported; the profiles observed have been 
specific to individual cell lines and culture/media conditions (36). Cisplatin (cis 
diamminedichloroplatinum(II)) forms primarily intrastrand crosslink adducts, which activate 
several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, 
and culminate in the activation of apoptosis. Cisplatin exposure induces IL-6, G-CSF, 
FGF secretion from specific cell lines (36). 
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We recently reported that reovirus-induced death of other human melanoma cell lines and 
human melanoma explants released a range of inflammatory cytokines and chemokines, 
while IL-10 secretion was abrogated. Reduced cytokine and chemokine production by co-
administration of cisplatin may allow increase in the dose of reovirus delivered to the tumor 
site. We and others have shown that the efficacy of reoviral cytotoxicity is increased in the 
setting of immune suppression mediated through reduction in humoral and cellular 
immunity with cyclosporine and cyclophosphamide (7, 14, 37). 
 
However, the abrogation of a local inflammatory cell kill by reovirus in this way may also 
be undesirable ultimately as it may reduce the efficiency of immune priming at the site of 
reoviral cytolysis, reduce migration of tumor-loaded antigen presenting cells to regional 
lymph nodes and the possibility of generating antigen-specific T cell immunity against the 
tumor (38). In addition, blunting the inflammatory response may also have a detrimental 
effect by counteracting the increased virus-associated vascular permeability and 
vasodilation, thereby potentially restricting viral distribution within tumour (39). 
 
The combination of systemic reovirus and a number of chemotherapeutic agents is 
currently being evaluated as phase I studies (REO-). These include attempts to enhance 
cytotoxicity with gemcitabine (REO 09), docetaxel (REO10) and carboplatin/paclitaxel 
(REO11, REO15 and REO16) in a number of indications. We are also attempting to exploit 
the immune modulating potential of chemotherapy using escalating doses of 
cyclophosphamide to attenuate the NARA response to reovirus (REO12). 
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